Low-added Sugar Dietary Intervention Study to Mitigate Glucose Intolerance and Improve Body Composition in Adults with Cystic Fibrosis: a Protocol of a Double-blind, Randomised Study

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 Dec 26

PMID 39725418

Authors

Swati Zaveri

Arlene Stecenko

William R Hunt

Amy Goss

Puneet Sharma

Terryl J Hartman

Kirk Easley

Joshua D Chandler

Tasha M Burley

Chris Driggers

Amy Ciccarella

Heather Zhou

Kristen Narlow

Thomas R Ziegler

Tanicia Daley

Priyathama Vellanki

Jessica Alvarez

Affiliations

Soon will be listed here.

Abstract

Introduction: People with cystic fibrosis (PwCF) are at high risk for developing cystic fibrosis (CF)-related diabetes (CFRD), which worsens morbidity and mortality. Although the pathological events leading to the development of CFRD are complex and not completely understood, dietary factors may play a role. For example, habitual intake of dietary added sugar (i.e., sugar not naturally occurring in foods) has been shown to be increased in PwCF and this excess intake of added sugar could increase the risk of CFRD.

Methods And Analysis/design: The goal of this ongoing double-blind, randomised, parallel-group clinical trial is to recruit approximately 60 clinically stable adults with CF to determine if a low-added sugar intervention improves beta-cell responsiveness and insulin sensitivity (Aim 1), reduces visceral adipose tissue (VAT) and other ectopic fat deposition (Aim 2) and improves plasma redox status (Aim 3) over 8 weeks compared with a typical CF diet. All foods will be provided. Participant selection criteria include confirmed CF diagnosis without CFRD, ≥18 years of age, and baseline estimated daily total added sugar intake >16 tsp. Eligible participants will be randomised to one of two arms: a low-added sugar diet (<5% of kcal from added sugars) or a high-added sugar (≥13% kcal from added sugars) diet. The two diets will be isocaloric and provide 35%-40% kcal from fat. Participants will be seen in the research unit for a screening, baseline/randomisation and 4-week and 8-week follow-up visits. Major study endpoints are changes in beta-cell responsiveness determined by a glucose-potentiated arginine stimulation test (primary endpoint), VAT assessed by magnetic resonance imagin (MRI) and fasted plasma cysteine redox potential. Diet tolerance, body weight and compliance are monitored weekly by phone by an unblinded study dietitian. All analyses will be intention-to-treat. Changes in study endpoints will be assessed with repeated-measures analysis. Models will assess the effects by study arm, time on study, and the interaction between arm and time on study.

Ethics And Dissemination: The National Institutes of Health (NIH) funds this study (R01 DK133523). The study protocol was approved by the Emory Institutional Review Board (IRB approval number: 000004517). Any protocol modifications will be reviewed and approved by the IRB prior to implementation and communicated with the study team and participants, as relevant.We will provide reports of the findings to the NIH and Emory IRB in regular progress reports and post the findings on www.

Clinicaltrials: gov (NCT05766774).

Trial Registration Number: This research study is registered at www.

References

Dunn W, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N . Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011; 6(7):1060-83. DOI: 10.1038/nprot.2011.335. View

ORiordan S, Robinson P, Donaghue K, Moran A . Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2009; 10 Suppl 12:43-50. DOI: 10.1111/j.1399-5448.2009.00587.x. View

Bridges N, Rowe R, Holt R . Unique challenges of cystic fibrosis-related diabetes. Diabet Med. 2018; . DOI: 10.1111/dme.13652. View

van der Haak N, King S, Crowder T, Kench A, Painter C, Saxby N . Highlights from the nutrition guidelines for cystic fibrosis in Australia and New Zealand. J Cyst Fibros. 2019; 19(1):16-25. DOI: 10.1016/j.jcf.2019.05.007. View

Smith C, Winn A, Seddon P, Ranganathan S . A fat lot of good: balance and trends in fat intake in children with cystic fibrosis. J Cyst Fibros. 2011; 11(2):154-7. DOI: 10.1016/j.jcf.2011.10.007. View

Cirnigliaro C, LaFountaine M, Dengel D, Bosch T, Emmons R, Kirshblum S . Visceral adiposity in persons with chronic spinal cord injury determined by dual energy X-ray absorptiometry. Obesity (Silver Spring). 2015; 23(9):1811-7. DOI: 10.1002/oby.21194. View

Harnack L, Stevens M, Van Heel N, Schakel S, Dwyer J, Himes J . A computer-based approach for assessing dietary supplement use in conjunction with dietary recalls. J Food Compost Anal. 2009; 21(Suppliment 1):S78-S82. PMC: 2151738. DOI: 10.1016/j.jfca.2007.05.004. View

Bettermann E, Hartman T, Easley K, Ferranti E, Jones D, Quyyumi A . Higher Mediterranean Diet Quality Scores and Lower Body Mass Index Are Associated with a Less-Oxidized Plasma Glutathione and Cysteine Redox Status in Adults. J Nutr. 2018; 148(2):245-253. PMC: 6251672. DOI: 10.1093/jn/nxx045. View

Schakel S, Sievert Y, Buzzard I . Sources of data for developing and maintaining a nutrient database. J Am Diet Assoc. 1988; 88(10):1268-71. View

10.

Gao L, Kim K, Yankaskas J, Forman H . Abnormal glutathione transport in cystic fibrosis airway epithelia. Am J Physiol. 1999; 277(1):L113-8. DOI: 10.1152/ajplung.1999.277.1.L113. View

11.

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

12.

Schafer F, Buettner G . Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 2001; 30(11):1191-212. DOI: 10.1016/s0891-5849(01)00480-4. View

13.

Thompson F, Midthune D, Kahle L, Dodd K . Development and Evaluation of the National Cancer Institute's Dietary Screener Questionnaire Scoring Algorithms. J Nutr. 2017; 147(6):1226-1233. PMC: 5443466. DOI: 10.3945/jn.116.246058. View

14.

Calvo-Lerma J, Hulst J, Boon M, Martins T, Ruperto M, Colombo C . The Relative Contribution of Food Groups to Macronutrient Intake in Children with Cystic Fibrosis: A European Multicenter Assessment. J Acad Nutr Diet. 2019; 119(8):1305-1319. DOI: 10.1016/j.jand.2019.01.003. View

15.

Hedrick V, Savla J, Comber D, Flack K, Estabrooks P, Nsiah-Kumi P . Development of a brief questionnaire to assess habitual beverage intake (BEVQ-15): sugar-sweetened beverages and total beverage energy intake. J Acad Nutr Diet. 2012; 112(6):840-9. PMC: 3379009. DOI: 10.1016/j.jand.2012.01.023. View

16.

Sievert Y, Schakel S, Buzzard I . Maintenance of a nutrient database for clinical trials. Control Clin Trials. 1989; 10(4):416-25. DOI: 10.1016/0197-2456(89)90006-8. View

17.

. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2016; 40(Suppl 1):S11-S24. DOI: 10.2337/dc17-S005. View

18.

Stallings V, Stark L, Robinson K, Feranchak A, Quinton H . Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc. 2008; 108(5):832-9. DOI: 10.1016/j.jada.2008.02.020. View

19.

Borowitz D, Baker R, Stallings V . Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002; 35(3):246-59. DOI: 10.1097/00005176-200209000-00004. View

20.

Fausnacht A, Myers E, Hess E, Davy B, Hedrick V . Update of the BEVQ-15, a beverage intake questionnaire for habitual beverage intake for adults: determining comparative validity and reproducibility. J Hum Nutr Diet. 2020; 33(5):729-737. DOI: 10.1111/jhn.12749. View